Over the last years, haploidentical transplantation has become a clinical reality for adult patients [1] [2] [3] lacking a matched donor. However, it is still widely perceived as an experimental procedure, and patients are often offered this type of procedure in a desperate situation, despite several encouraging reports, [1] [2] [3] [4] which negatively impacts on the relapse rate.
At the time we started this study, the two major problems were a high transplant-related mortality, partially because of numerous infectious complications 2 and a high relapse rate, the latter mostly because of the advanced disease stage at the time the transplant was considered.
In T-cell-depleted transplantation, the expansion of the few T cells in the graft is not prevented by immunosuppression, but because of the paucity of the starting population, immune recovery takes a very long time. 5 At the time we started the study, NK alloreactivity started to emerge as a major player in the GVL effect of the transplant, 6 which was confirmed later on 4 and we have incorporated these data from the start in choosing the donor. Since T-celldepleted transplants are 'per se' at a higher risk of relapse, 7 we thought that the other parameters upon which to play were T cell add-back and the type of growth factors used post-transplant. This is why we launched a DLI dosefinding study in a cohort of particularly bad risk patients, in order to test the feasibility of this approach, to see how it would impact immune reconstitution and disease control. Another point we wanted to incorporate into the study was the choice of the growth factor: emerging data suggested a negative role of G-CSF on immune function posttransplant. [8] [9] [10] [11] [12] [13] [14] [15] We therefore planned to start with delayed administration of G-CSF, and to replace it, in a second step, with GM-CSF. Finally, we chose to slightly modify the conditioning regimen, in order to make it less toxic and possibly less prone to promoting graft rejection.
Patients and methods

Conditioning
The conditioning regimen consisted of melphalan: 60 mg/ m 2 /d (days À9, À8), TBI: 5 Â 2 Gy (days À7 to À3), fludarabine: 40 mg/m 2 /day (days À7 to À3), ATG Fresenius: 5 mg/kg/day (days À6 to À1)+high-dose steroids (5 mg/kg the first day, 2 mg/kg the four other days) and cyclosporin A: 5 mg/kg/day (days À7 to À2). TBI was reduced to 5 Â 2 Gy to reduce lung damage and toxicity of conditioning in these heavily pretreated patients. An interval of 12 h between Fludarabine administration and TBI was chosen to avoid radiosensitization. Pre-SCT/CSA was added to decrease the risk of graft rejection. For rapidly progressive disease, cytarabine (1 g/m 2 twice daily) was added at days À17, À16. This was needed in three patients. Melphalan was chosen because of the high frequency of cardiac insufficiency because of multiple previous treatments, including autologous transplantation and anthracycline use. If contraindicated (previous irradiation), which was the case in three patients, TBI was replaced with busulfan (myeloid disorders: one case) or cyclophosphamide (lymphoid diseases: two cases) at standard transplant doses. Thus, as detailed in Table 1 , all patients received melphalan, ATG, cyclosporine, prednisone. Nine had TBI and three busulfan or cyclophosphamide. No post-transplant immune suppression was given.
Peripheral blood harvest engineering PBSC were depleted in two steps using the Isolex 300i: CD34 positive selection was followed by further B and T depletion using anti-CD4, -CD8 and -CD19 antibodies. The additional B-cell depletion was performed to reduce the B-cell content of the graft, therefore decreasing the risk of post-HSCT PTLD. CD3 were adjusted to a fixed dose of 5 Â 10 4 /kg in the graft for all patients.
Infections: prophylaxis and monitoring
All patients received an aerosol of pentamidine pretransplant. Post-transplant prophylaxis consisted of cotrimoxazole 3 times a week, acyclovir 3 Â 5 mg/kg/day, fluconazole 400 mg/day and amphotericin B aerosols 4 times a day. Apart from standard culture monitoring, quantitative PCR on peripheral blood was performed for the detection of CMV (twice a week), HHV6 (twice a week), toxoplasma (once a week) and EBV (once a week). A CT-scan of sinuses and chest was performed pretransplant and post-transplant in cases of persistent fever on antibiotics.
Donor lymphocytes infusions and growth factors policy DLI were given using the negative fraction of the CD34-positive selection. CD3 were measured using flow cytometry and aliquots containing 1 Â 10 4 CD3/kg kept frozen. These lymphocytes were therefore harvested during G-CSF mobilization. The rationale for using these was that they had proven to be less alloreactive in terms of acute GVHD, while maintaining a potential for cGVHD. The first dose was fixed at 3 Â 10 4 CD3/kg at day 28. If the two first patients developed aGVHD (which was the case), the next step was to give 1 Â 10 4 CD3/kg monthly for 3 months. If this was well tolerated, and if early relapse occurred, escalated doses of: 1, 3, 10 Â 10 4 /kg would be given monthly. In the event that this resulted in no better control of the disease and/or in too many cases of GVHD, a replacement of G-CSF with GM-CSF was planned. As a result, in the nine first patients, G-CSF was started at day 5. Administration was delayed to avoid its presence immediately post-transplant, to decrease its immunosuppressive effects during the early phase of antigen presentation to lymphocytes. In the last three patients, G-CSF was replaced with GM-CSF 100 mg/m 2 from day 1, with 3 monthly DLI of 3 Â 10 4 CD3/kg, as a next step to improve post-transplant immunity. All these growth factors were discontinued when the ANC was greater than 1000/ml. For overt relapses, 10 5 and 5 Â 10 5 CD3/kg were given at two weekly intervals.
Patients and donors
In all, 12 consecutive patients were included, the characteristics of whom are displayed in Table 2 , with the type of donor and NK alloreactivity. When possible, the donor was chosen with NK reactivity in the GVH direction (seven out of 12 cases). It is worth remarking that nine patients had refractory disease (primary or relapses), of which four rapidly progressed and received Ara-C. Seven had had a previous autologous peripheral blood stem cell transplant. Only three were at a slightly better risk: a second chronic phase CML who first responded to STI and was losing his response at the time of transplant, a second good partial PR in an AML patient relapsing 3 month post-transplant and a partial remission of RAEB. Their ages ranged from 18 to 55 years. Their median follow-up is 12 months (range 6-29). When possible (ALL), a monthly follow-up of residual disease was carried out using a methodology previously described. 16 Results
Engraftment and early transplant-related complications
All patients engrafted at a median of 14 days. All were in CR post-transplant. Details of engraftment are described in Table 3 . The following complications were observed during the first 6 weeks (before any effect of the DLI was seen on lymphocytes counts): CMV reactivation (defined as two consecutive positive PCRs) in 10 patients, HHV6 in one, toxoplasmosis in two, aspergillosis in four and VOD (treated with defibrotide) in one. All these infections resolved with treatment. aGVHD, grade II, occurred in patient 12 (who was on GM-CSF), at day 27.
DLI and GVHD
Overall, 11 patients received DLI according to the dosefinding schedule described above. The results, in terms of aGVHD are detailed in Table 4 . To briefly summarize, the dose of 3 Â 10 4 CD3/kg was found to produce aGVHD in the two first patients. The three monthly infusions of 1 Â 10 4 CD3/kg were perfectly safe in patients who had received G-CSF from day 5. Trying to give escalated doses (1, 3, 10 Â 10 4 CD3/kg) produced aGVHD in all patients after the second or third dose. Therapeutic DLI (10 5 and 5 Â 10 5 CD3/kg at a 2 week interval) induced aGVHD when given before month 6, and no GVHD after. The switch to GM-CSF from day 1 post-transplant showed a tendency to more aGVHD, especially after several DLI.
Effect of DLI on immune reconstitution
The effect of the first DLI was evaluated by measuring the average week 2 and 3 postinfusion CD4, CD8 and CD56 counts, in 11 patients, before any GVHD occurred. There was a striking increase in these parameters, as shown in Figure 1 . The most impressive was the CD4 increase (from 14 to 97/ml), which reached a value that, according to published data, is achieved only after 6-9 months in patients who received G-CSF (2) and around 90 days with no G-CSF (15) . Out of these 11 patients, six had no GVHD (thus no immunosuppression) and therefore could be clinically evaluated for the efficacy of these changes in terms of infections. Of those six, during the first month, four had a CMV reactivation (by PCR), one had an HHV6 infection (biopsy proven), two aspergillosis that was treated using voriconazole and one toxoplasmosis treated with clindamycin and pyrimethamine. All responded. After month 2 and the rise in CD4 cells, there was no reactivation of CMV, HHV6, aspergillosis or toxoplasmosis in these six patients. The only infection events were a rise in the number of EBV copies (patient 5) that was considered a risk for developing a PTLD and successfully treated with rituximab, and one RSV infection at 6 months (patient 6) that was treated successfully with ribavirine aerosols. In the other five patients, in whom GVHD occurred after DLI, immunosuppressive treatment had to be initiated (median time 8 weeks) and these patients suffered from the usual opportunistic infections: CMV (3), aspergillosis (2), toxoplasmosis (1). These results seem to demonstrate that DLI are efficient in restoring early immunocompetence, provided one finds the narrow window where no GVHD occurs; the benefit is otherwise lost.
Replacement of G-CSF with GM-CSF
In patients 10, 11 and 12, G-CSF starting at day 5 was replaced with GM-CSF starting at day 1. These patients were planned to receive three monthly DLI at the dose of 1 Â 10 4 CD3/kg. However, while this scheme had produced no GVHD in patients on G-CSF, grade II aGVHD occurred in two patients, one before DLI and one after 2 DLI. This highlights the role of post-transplant growth factors and prompted us to slightly modify the timing of GM-CSF administration and the number of DLI in our future patients.
Overall outcome and mortality
Transplant-related mortality was 0 at days 100 and 365. Two patients (patients 1 and 2) can be considered as having died from late transplant complications. These two patients, who had received the higher doses of CD3, remained in complete remission but died of infectious complications occurring in the context of late cGVHD exacerbation and increased immunosuppression at months 19 and 28, respectively. Overall, six patients relapsed at months 3, 4, 4, 6, 8, 9 and they all died. Therapeutic DLI (10 5 and 5 Â 10 5 CD3/kg) were given at a 2-week interval in these patients, except in two (patient 3 with CNS relapse and patient 8 who had already an aGVHD). These DLI induced aGVHD in two patients (relapsing before month 6) and none in patients relapsing after month 6. Only one of them, patient 9, who received Mylotarg, followed 2 weeks later by DLI, had a new complete remission, at the time GVHD occurred, but died of severe complications possibly related to Mylotarg. As far as this is relevant with such a small series, as on April 2002, the 1-year probability of survival was 50% as was a relapse-free survival (all the deaths being because of relapse) with a median follow-up of 9 months.
Discussion
Despite the small size of this series, several conclusions can be drawn. The first is that transplant-related mortality was quite acceptable (TRM 0% at days 100 and 365) with our conditioning regimen in this cohort of heavily pretreated patients. It is worth noticing that there was only one VOD (patient 5 in whom TBI had been replaced with cyclophosphamide), although many patients had several risk factors for it, and we can only speculate why: reduced TBI intensity, the absence of cyclophosphamide in the regimen, the use of high-dose methyl-prednisolone pretransplant? Another point worth mentioning is the absence of rejection despite a rather low average CD34-positive cell dose. Again, we can only speculate whether increasing pretransplant immunosuppression has played any role. The baseline is at day 28 and the values post-DLI are a mean of days 42 and 47 counts.
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Another conclusion can be derived from our study: DLI are feasible in this group of patients, and induce no GVHD if restricted to 1 Â 10 4 CD3/kg monthly, in patients who have received G-CSF from day 5 post-transplant. Escalated doses always induce GVHD.
Are these DLI useful? In terms of a GVL effect, no conclusion can be drawn, given the size of the sample. One can simply note that a relapse rate of 50% is not unexpected in patients transplanted with progressive refractory disease and is even encouraging. The case of patient 4 ( Figure 2 ) might suggest a possible activity, but this remains anecdotal. There is some indication that GVHD had a role in preventing relapse: of the five patients who developed a GVHDXgrade II after prophylactic DLI (P1, P2, P10, P11, P12), there was only one relapse (patient 8). However, the price to pay was not negligible, since two patients died of late exacerbation of chronic GVHD, and we therefore do not think that this effect should be sought. For patients in whom GVHD was provoked by therapeutic DLI, this did not control the disease, except in patient 9, where it might have contributed. In terms of immune reconstitution, as shown by CD4 numbers when compared to published data 2, 15 and viral reactivation, the answer seems to be yes, as long as no GVHD occurs. In the latter case, the benefit in terms of immunity and infections is completely wiped out by the immunosuppressive drugs needed to control GVHD. Therefore, one should attempt to give at least one donor lymphocyte infusion (the first one seems to be the most important in terms of increasing the number of CD4 T cells and preventing opportunistic and viral infection), while making every effort to avoid aGVHD more severe than grade I. The scheme using G-CSF from day 5 and monthly doses of 10 4 CD3 is effective in this way. Should we try to improve on it? Given the literature data about the effect of G-CSF 15 and the possible favorable impact of GM-CSF when combined to DLI in patients relapsing after conventional HLA-identical transplant (H. Kolb, personal communication), we are currently attempting to use GM-CSF and a single DLI. It is possible that replacing G-CSF with GM-CSF may lead to more GVHD as we have seen in one case, and we are now using it starting from day 5 instead of day 1, to avoid its presence during the early 'cytokine storm', and a single DLI is still planned at day 28. Quite obviously, choosing a donor with NK alloreactivity remains most important, and we tried, and will continue to go in this direction. Nevertheless, playing on the T-cell compartment could also have a role both in promoting a GVL effect and in the prevention of infections.
In the future, DLI enriched in specific antileukemic CTL (such as anti-WT1) will be added to the post-transplant treatment: But as it stands, this protocol could produce very satisfactory results, when haploidentical transplant emerges as an alternative procedure, that can safely be proposed for patients for whom an indication exists (e.g. Philadelphia-positive ALL with no donor) and no longer as a desperate treatment performed in patients in refractory relapse after several treatment approaches. following transplant and the three monthly DLI.
